The efficacy of venlafaxine in the treatment of women with stress urinary incontinence

[1]  E. Iacovelli,et al.  Venlafaxine and Bladder Function , 2005, Clinical neuropharmacology.

[2]  F. Salvo,et al.  Venlafaxine-Induced Urinary Incontinence Resolved After Switching to Sertraline , 2005, Clinical neuropharmacology.

[3]  A. Grant,et al.  Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. , 2005, The Cochrane database of systematic reviews.

[4]  L. Hansen.  Venlafaxine-induced increase in urinary frequency in 3 women. , 2004, The Journal of clinical psychiatry.

[5]  S. Watson,et al.  Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia , 2004, Biological Psychiatry.

[6]  R. Bump,et al.  Validation of two global impression questionnaires for incontinence. , 2003, American journal of obstetrics and gynecology.

[7]  F. Bymaster,et al.  Dual Monoamine Modulation for Improved Treatment of Major Depressive Disorder , 2003, Journal of clinical psychopharmacology.

[8]  K. Thor,et al.  Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. , 2002, Life sciences.

[9]  P. Norton,et al.  Duloxetine versus placebo in the treatment of stress urinary incontinence. , 2002, American journal of obstetrics and gynecology.

[10]  D. Wong,et al.  Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors , 2001, Neuropsychopharmacology.

[11]  D. Moon,et al.  The effects of a selective noradrenaline reuptake inhibitor on the urethra: an in vitro and in vivo study , 2001, BJU international.

[12]  M E Phelps,et al.  Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. , 2001, Archives of general psychiatry.

[13]  N. Pitsikas.  Duloxetine Eli Lilly & Co. , 2000, Current opinion in investigational drugs.

[14]  A. Grant,et al.  Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. , 2007, European urology.

[15]  V. Nitti.  Duloxetine: a new pharmacologic therapy for stress urinary incontinence. , 2004, Reviews in urology.

[16]  M.,et al.  Symptom and Quality of Life Assessment , 2002 .

[17]  N. Votolato,et al.  Serotonergic Antidepressants and Urinary Incontinence , 2000, International Urogynecology Journal.

[18]  T. Wagner,et al.  Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL) , 1999, Urology.

[19]  T. Bavendam,et al.  Quality of life of persons with urinary incontinence: development of a new measure. , 1996, Urology.